转录因子MEF2D对MLL重排急性髓系白血病的维持至关重要
MLL重排(MLL-r)急性髓系白血病(AML)约占全部AML的10%,预后较差。研究发现转录因子MEF2D是MLL-r AML中超级增强子相关的高表达基因,敲除MEF2D可显著损害白血病生长、诱导髓系分化并延缓体内肿瘤进展。机制上,MEF2D结合并抑制CEBPE顺式调控区的染色质可及性,抑制以CEBPE为核心的髓系分化程序;MEF2D受HOXA9正向调控,且MEF2D下调是DOT1L抑制剂抗白血病作用的重要机制。
要点
- MEF2D在MLL-r AML中高表达且与超级增强子相关。
- 敲除MEF2D损害白血病生长、诱导分化并延缓体内进展。
- MEF2D-CEBPE轴调控白血病自我更新与分化阻滞。
核心结论
- MEF2D在MLL-r AML中起关键作用,MEF2D-CEBPE轴是调控白血病细胞自我更新和分化阻滞的重要转录机制。
研究设计与样本
- 研究采用基因敲除、染色质分析及人急性白血病样本检测等方法,探讨MEF2D在MLL-r AML中的功能与机制。
主要发现
- MEF2D是MLL-r AML中超级增强子相关的高表达基因。
- 敲除MEF2D显著损害白血病生长、诱导髓系分化并延缓体内肿瘤进展。
- MEF2D缺失强烈激活以CEBPE为核心的髓系分化程序。
- 染色质分析显示MEF2D结合并抑制CEBPE顺式调控区的染色质可及性。
- 人急性白血病样本中MEF2D表达与CEBPE表达呈强负相关。
关键数值与推荐
- 敲低CEBPE可部分挽救MEF2D缺失引起的细胞生长缺陷和髓系分化。
- MEF2D受HOXA9正向调控,其下调是DOT1L抑制剂抗白血病效应的重要机制。
临床怎么用
- MEF2D及其下游CEBPE轴可能作为MLL-r AML的潜在治疗靶点。
- DOT1L抑制剂的抗白血病作用部分通过下调MEF2D实现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukemia (AML) with MLL-rearrangement (MLL-r) comprises ∼10% of all AML cases and portends poor outcomes. Much remains uncovered on how MLL-r AML drives leukemia development while preventing cells from normal myeloid differentiation. Here, we identified that transcription factor MEF2D is a super-enhancer-associated, highly expressed gene in MLL-r AML. Knockout of MEF2D profoundly impaired leukemia growth, induced myeloid differentiation, and delayed oncogenic progression in vivo. Mechanistically, MEF2D loss led to robust activation of a CEBPE-centered myeloid differentiation program in AML cells. Chromatin profiling revealed that MEF2D binds to and suppresses the chromatin accessibility of CEBPE cis-regulatory regions. In human acute leukemia samples, MEF2D expression showed a strong negative correlation with the expression of CEBPE. Depletion of CEBPE partially rescued the cell growth defect and myeloid cell differentiation induced by the loss of MEF2D. Lastly, we show that MEF2D is positively regulated by HOXA9, and downregulation of MEF2D is an important mechanism for DOT1L inhibitor-induced antileukemia effects. Collectively, our findings suggest that MEF2D plays a critical role in human MLL-r AML and uncover the MEF2D-CEBPE axis as a crucial transcriptional mechanism regulating leukemia cell self-renewal and differentiation block.
引用
- Zhao L, Zhang P, Galbo PM, et al. Transcription factor MEF2D is required for the maintenance of MLL-rearranged acute myeloid leukemia. Blood Adv. 2021. PMID: 34597364. doi:10.1182/bloodadvances.2021004469
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。